Dasatinib
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Dasatinib, (former BMS 354825), is an orally available small-molecule multikinase inhibitor. It potently inhibits BCR-ABL and SRC-family kinases (SRC, LCK, YES, FYN), but also c-KIT, PDGFR-alpha and beta, and ephrin receptor kinase.Dasatinib is about 300 times more potent than imatinib in cells expressing unmutated BCR-ABL in vitro. The drug has demonstrated activity against clinically relevant mutations, including those associated with poor prognosis during ongoing imatinib therapy.Dasatinib is approved for the treatment of patients with BCR-ABL-positive chronic myeloid leukemia (CML), resistant or intolerant to imatinib in chronic, accelerated, and blast phase. It also is approved for the treatment of Philadelphia Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to imatinib.A single daily dose of 100 mg in chronic phase CML results in high hematologic and molecular remission rates and prolongation of survival. In accelerated and blastic phase as well as in ALL, 70 mg twice daily is recommended. Complete hematologic and cytogenetic remissions (CR) frequently occur even in this patient group with poor prognosis. Remissions however are very short.Side effects of dasatinib are frequent but mostly moderate and manageable and include cytopenias and pleural effusions. The role of dasatinib in other diseases, including solid tumors, has to be identified.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At present, dasatinib (D), a tyrosine-kinase inhibitor that is Food and Drug Administration (FDA)-approved for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)22, and quercetin (Q), a natural plant-derived flavonoid with anti-inflammatory, antioxidant and antineoplastic properties23 potentially by modulating autophagy24, are the best-characterized senolytics9.”
From Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial (2023) · cites this paper as [22]
Citations
Cites
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice
Lindahl, P., Johansson, B. R., Levéen, P., & Betsholtz, C. (1997) · Science · doi:10.1126/science.277.5323.242 · Cited by 2,226
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Research works printed but not linked: 9
- Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008:1–8
- Evans TRJ, Morgan JA, Van den Abbeele AD, et al (2005) Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol 23:16S:abstr. 3034
- Hochhaus A, Neubauer A, Mueller MC, et al (2008b) Imatinib discontinuation after imatinib/interferon alpha combination therapy is associated with continuous responses in the majority of patients. Haematologica 93:abstr. 0927
- Jabbour E, Cortes J, O’Brien S et al (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance Semin Hematol 44:25–31
- Johnson FM, Chiappori A, Burris H, et al (2007) A phase I study (CA180021-segment 2) of dasatinib in patients (pts) with advanced solid tumors. J Clin Oncol 25:18S:abstr. 14042
- Nowell P, Hungerford DA (1960) A minute chromosome in human granulocytic leukemia. Science 132:1497
- Quintas-Cardama A, Kantarjian H, O’Brien S, et al (2007b) Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukaemia. Haematologica 92(Suppl 1):abstr. 0359
- Verstovsek S, Tefferi A, Cortes J et al (2008) Phase II study of dasatinib in philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3907–3915
- Yu EY, Wilding G, Posadas E, et al (2008) Dasatinib in patients with hormone refractory progressive prostate cancer: a phase II study. J Clin Oncol 26:15S:abstr. 5165
Cited by
Bendall, S. C., Simonds, E. F., Qiu, P., Amir, E.-A. D., Krutzik, P. O., Finck, R., Bruggner, R. V., Melamed, R., Trejo, A., Ornatsky, O. I., et al. (2011) · Science · doi:10.1126/science.1198704 · Cited by 2,279
Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 334
Orr, M., Gonzales, M., Garbarino, V., Kautz, T., Palavicini, J., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J., Zare, H., Xu, P., et al. (2023) · doi:10.21203/rs.3.rs-2809973/v1 · Cited by 319
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal Cancer
Baker, A.-M., Cox, T. R., Bird, D., Lang, G., Murray, G. I., Sun, X.-F., Southall, S. M., Wilson, J. R., & Erler, J. T. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq569 · Cited by 206
Metadata
- Authors
- Lindauer, M., & Hochhaus, A.
- Affiliations
- SLK-Kliniken Heilbronn (DE)
- Corresponding author
- Lindauer, Markus
- ORCID
- Hochhaus, Andreas
- Venue
- Recent Results in Cancer Research
- Publisher
- Springer Berlin Heidelberg
- Published
- 2009-10-07
- Volume
- 184
- Pages
- 83-102
- ISSN
- 0080-0015 (ISSN-L)
- OpenAlex
- W4256391755
- Cited by
- 57
- References
- 58
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 2 · 2018: 4 · 2017: 2 · 2015: 4 · 2014: 4 · 2013: 5 · 2012: 4
- FWCI
- 19.07
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Recent results in cancer research/Recent Results in Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, BCR-ABL, Src family kinases, multikinase inhibitor, chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, imatinib resistance, CD117, PDGFR, cytopenia, pleural effusion, hematologic remission, cytogenetic remission
- MeSH terms
- Dasatinib, Clinical Trials as Topic, Humans, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Oncogene Proteins v-abl, Proto-Oncogene Proteins c-kit, src-Family Kinases, Receptor, Platelet-Derived Growth Factor alpha, Protein Kinase Inhibitors, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib. https://app.cochat.ai/papers/10.1007/978-3-642-01222-8_7
- The paper
- Lindauer, M., & Hochhaus, A. (2010). Dasatinib. Recent Results in Cancer Research. https://doi.org/10.1007/978-3-642-01222-8_7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.